These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 9327421)

  • 1. [New animal models for the diseases of central nervous systems and screening of new drugs].
    Nabeshima T; Sasa S
    Nihon Yakurigaku Zasshi; 1997 Sep; 110(3):126-8. PubMed ID: 9327421
    [No Abstract]   [Full Text] [Related]  

  • 2. Correct assessment of new compounds using in vivo screening models can reduce false positives.
    Bueters TJ; Hoogstraate J; Visser SA
    Drug Discov Today; 2009 Jan; 14(1-2):89-94. PubMed ID: 18840543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Translational research in central nervous system drug discovery.
    Hurko O; Ryan JL
    NeuroRx; 2005 Oct; 2(4):671-82. PubMed ID: 16489374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative psychology and the grand challenge of drug discovery in psychiatry and neurodegeneration.
    Brunner D; Balcı F; Ludvig EA
    Behav Processes; 2012 Feb; 89(2):187-95. PubMed ID: 22155361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Translational medicine 2006.
    Persiani S
    IDrugs; 2006 Apr; 9(4):253-5. PubMed ID: 16596476
    [No Abstract]   [Full Text] [Related]  

  • 6. Failed trials for central nervous system disorders do not necessarily invalidate preclinical models and drug targets.
    Bespalov A; Steckler T; Altevogt B; Koustova E; Skolnick P; Deaver D; Millan MJ; Bastlund JF; Doller D; Witkin J; Moser P; O'Donnell P; Ebert U; Geyer MA; Prinssen E; Ballard T; Macleod M
    Nat Rev Drug Discov; 2016 Jul; 15(7):516. PubMed ID: 27312728
    [No Abstract]   [Full Text] [Related]  

  • 7. E-pharmacophore-based screening of mGluR5 negative allosteric modulators for central nervous system disorder.
    Vijaya Prabhu S; Singh SK
    Comput Biol Chem; 2019 Feb; 78():414-423. PubMed ID: 30621985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tools in the Design of Therapeutic Drugs for CNS Disorders: An up-to-date Review.
    Sahu JK; Mishra AK
    Curr Mol Pharmacol; 2018; 11(4):270-278. PubMed ID: 30129422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using NMR approaches to drive the search for new CNS therapeutics.
    Borsook D; Becerra L
    Curr Opin Investig Drugs; 2010 Jul; 11(7):771-8. PubMed ID: 20571972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders.
    Ivachtchenko AV; Lavrovsky Y; Okun I
    J Alzheimers Dis; 2016 May; 53(2):583-620. PubMed ID: 27232215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Removing obstacles in neuroscience drug discovery: the future path for animal models.
    Markou A; Chiamulera C; Geyer MA; Tricklebank M; Steckler T
    Neuropsychopharmacology; 2009 Jan; 34(1):74-89. PubMed ID: 18830240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploratory clinical testing of neuroscience drugs.
    Choi DW
    Nat Neurosci; 2002 Nov; 5 Suppl():1023-5. PubMed ID: 12403975
    [No Abstract]   [Full Text] [Related]  

  • 13. Central nervous system drug development: an integrative biomarker approach toward individualized medicine.
    Gomez-Mancilla B; Marrer E; Kehren J; Kinnunen A; Imbert G; Hillebrand R; Bergström M; Schmidt ME
    NeuroRx; 2005 Oct; 2(4):683-95. PubMed ID: 16489375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The possible role of substances inhibiting protein synthesis on the treatment of the spongiform encephalopathies.
    Schwarz KO
    Med Hypotheses; 1988 Nov; 27(3):189-91. PubMed ID: 3211014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a RapidFire mass spectrometry assay and a fluorescence assay for the discovery of kynurenine aminotransferase II inhibitors to treat central nervous system disorders.
    Lu H; Kopcho L; Ghosh K; Witmer M; Parker M; Gupta S; Paul M; Krishnamurthy P; Laksmaiah B; Xie D; Tredup J; Zhang L; Abell LM
    Anal Biochem; 2016 May; 501():56-65. PubMed ID: 26874021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal erythropoietin therapy in nervous system disorders.
    Genc S; Zadeoglulari Z; Oner MG; Genc K; Digicaylioglu M
    Expert Opin Drug Deliv; 2011 Jan; 8(1):19-32. PubMed ID: 21143002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of CNS disorders and evaluation of therapy using structural and functional MRI.
    Rudin M; Mueggler T; Allegrini PR; Baumann D; Rausch M
    Anal Bioanal Chem; 2003 Nov; 377(6):973-81. PubMed ID: 12942228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New animal models for drug discovery research: focus on cardiovascular diseases].
    Nakashima M; Umemura K; Takiguchi Y
    Nihon Yakurigaku Zasshi; 1993 Sep; 102(3):191-9. PubMed ID: 8406232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Localized Tacrolimus Delivery Repairs the Damaged Central Nervous System.
    Willerth SM
    EBioMedicine; 2017 Dec; 26():4-5. PubMed ID: 29195745
    [No Abstract]   [Full Text] [Related]  

  • 20. Behavioral tests in acute and chronic toxicity studies.
    Brimblecombe RW
    Pharmacol Ther B; 1979; 5(1-3):413-5. PubMed ID: 493322
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.